Results for tag: "Sezary Syndrome Drug"

Sezary Syndrome is a rare form of cutaneous T-cell lymphoma, a type of non-Hodgkin lymphoma. Treatment for Sezary Syndrome typically involves a combination of chemotherapy, radiation therapy, and immunotherapy. Drugs used to treat Sezary Syndrome include bexarotene, denileukin diftitox, romidepsin, and vorinostat. Bexarotene is a retinoid drug that works by targeting the abnormal T-cells that cause Sezary Syndrome. Denileukin diftitox is a fusion protein that works by targeting the abnormal T-cells and blocking their growth. Romidepsin is a histone deacetylase inhibitor that works by blocking the growth of abnormal T-cells. Vorinostat is a histone deacetylase inhibitor that works by blocking the growth of abnormal T-cells. Companies in the Sezary Syndrome Drug market include Eisai Co., Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, and Sun Pharmaceutical Industries Ltd. Show Less Read more